Emerging data suggest this peptide, a dual stimulator targeting both GLP-1 and another hormone, could represent a notable development for body treatment. Preliminary patient tests have demonstrated impressive reductions in abdominal tissue, potentially surpassing existing weight-loss treatments. Nevertheless , additional study is necessary to fully